

# United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/686,964	10/12/2000	Geert Macrtens	2551-48	5719
23117 7	590 09/09/2004		EXAMINER	
NIXON & VANDERHYE, PC			HILL, MYRON G	
1100 N GLEBE ROAD 8TH FLOOR		ART UNIT	PAPER NUMBER	
	, VA 22201-4714		1648	
			DATE MAILED: 09/09/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

•"	Application No.	Applicant(s)			
	09/686,964	MAERTENS ET AL.			
Office Action Summary	Examiner	Art Unit			
	Myron G. Hill	1648			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply lf NO period for reply is specified above, the maximum statutory period we Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) day- rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
Responsive to communication(s) filed on 14 Ju     This action is <b>FINAL</b> . 2b) ☐ This     Since this application is in condition for allowant closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) ⊠ Claim(s) <u>36- 49, 62- 110</u> is/are pending in the a 4a) Of the above claim(s) <u>42, 43, 79, 89, 103, a</u> 5) □ Claim(s) is/are allowed. 6) ⊠ Claim(s) <u>36- 41, 44- 49, 62- 78, 80- 88, 90- 102</u> 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and/or	<u>nd 105- 107</u> is/are withdrawn fro 2 <u>, 104 and 108- 110</u> is/are rejecte				
9)☐ The specification is objected to by the Examine	r.				
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.					
Applicant may not request that any objection to the or Replacement drawing sheet(s) including the correction 11) The oath or declaration is objected to by the Ex	ion is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Applicati ity documents have been receive ı (PCT Rule 17.2(a)).	on No ed in this National Stage			
Attachment(s)  1) Notice of References Cited (PTO-892)	4) 🔲 Interview Summary	(PTO-413)			
<ul> <li>1) Notice of References Cited (PTO-992)</li> <li>2) Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)</li> <li>Paper No(s)/Mail Date 6/14/04.</li> </ul>	Paper No(s)/Mail Da				

This action is in response to paper filed 6/14/04.

Election/Restrictions

Newly submitted claims 79, 89, 103, and 105- 107 are directed to an invention that is independent or distinct from the invention originally claimed for the following reasons: they are drawn to methods of making a product (kit) and have different method steps for each variation of the method. The original claims were drawn to a product, not a method of making a product and the methods would have been subject to restriction because there are many methods to make the same product.

Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claims 79, 89, 103, and 105- 110 are withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

Claims 36- 41, 44- 49, 62- 78, 80- 88, 90- 102, 104 and 108- 110 are under consideration.

#### Information Disclosure Statement

The information disclosure statement filed 6/14/04 fails to comply with 37 CFR 1.98(a)(2), which requires a legible copy of each U.S. and foreign patent; each publication or that portion which caused it to be listed; and all other information or that

Art Unit: 1648

portion which caused it to be listed. It has been placed in the application file, but the information referred to therein has not been considered. No copies were received with the IDS paper.

## **Rejections Maintained or Necessitated By Amendment**

### Claim Rejections - 35 USC § 112

Claims 44- 49 and new claims 83- 86 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claims are drawn to epitopes comprising at least one amino acid residue selected from the recited group of single amino acids.

Applicant argues that the specification discloses the recited residues on page 17 and these are isolate specific amino acids as well as amended the claims to recite epitopes of 5- 6 residues. Applicant argues that one of ordinary skill in the art would appreciate the description as exemplified. Lastly, the Examiner is urged to appreciate that the epitopes of the claims require more than one amino acid.

Applicant's arguments have been fully considered and not found persuasive.

The claims do not recite isolate specific amino acids and neither does the specification at page 17, lines 6- 10. There is merely a list of single amino acids and a list of combinations.

Applicant has not taught specific linear or conformational epitopes that comprise the recited residues, or what properties (specific sequences that antibodies bind to) these epitopes have over the many other epitopes in the NS3 polypeptide of HCV. Thus, it is concluded that applicant did not have in their possession the full range of epitopes claimed.

The rejection is maintained and applies to the new claims listed above.

### Claim Rejections - 35 USC § 103

Claims 36- 38, 40, 41, and 62- 76, 81 87, 88 are rejected under 35 U.S.C. 103(a) as being unpatentable over Seidel et al. (US 6036579) and Harlow and Lane.

The claims are drawn to an HCV NS3 immunoassay wherein sulphonation and desulphonation is added in at least one step.

Applicant argues that the method of sulphonation and desulphonation leads to a product with better activity and/or conformation closer to native protein then the products made by the prior art methods.

Applicant's arguments have been fully considered and not found persuasive.

The Office considers a "kit" claim to be a product. That product is what the kit contains/comprises.

Application/Control Number: 09/686,964

Art Unit: 1648

It is noted that the claims have been amended to recite sulphonation and desulphonation as product by process steps. The product claimed now is desulphonated.

Applicant has not pointed out how the product is different than the cited prior art or is different from the previously claimed product.

Page 15 of the specification discloses that DTT is used to desulphonate the product. DTT is used in the prior art as cited in the rejection of record. Thus, the product of the prior art is desulphonated and is the same as the now claimed product.

The rejection of record is maintained for reasons above and as cited in the prior action and is also applied to the new claims.

Claims 39, 44- 49, 80, and 82- 86 are rejected under 35 U.S.C. 103(a) as being unpatentable over Seidel et al. (US 6036579) and Harlow and Lane as applied to claims 36- 38, 40, 41, and 44- 76 above, and further in view of Leroux-Roels.

Applicant argues that the method of sulphonation and desulphonation leads to a product with better activity and/or conformation closer to native protein then the products made by the prior art methods.

Applicant's arguments have been fully considered and not found persuasive.

The basis of the rest of the rejection as stated in the previous rejection.

Applicant has not argued that the claimed sequence is taught by Leroux-Roels (SEQ ID# 2) is not the same as SEQ ID# 18.

The rejection is maintained and is also applied to the new claims.

Application/Control Number: 09/686,964

Art Unit: 1648

Claims 77, 78, 104, and 108- 110 are rejected under 35 U.S.C. 103(a) as being unpatentable over Seidel et al. (US 6036579) and Harlow and Lane as applied to claims 36- 38, 40, 41, and 44- 76 above, and further in view of lcardi *et al*.

Applicant argues that the method of sulphonation and desulphonation leads to a product with better activity and/or conformation closer to native protein then the products made by the prior art methods.

Applicant's arguments have been fully considered and not found persuasive.

The basis of the rejection is as stated in the previous two rejections.

Applicant has not pointed out how the product is different or how lcardi et al.

do not make obvious the controls used in the claimed product.

The rejection of record is maintained for reasons above and as cited in the prior action and is also applied to the new claims.

#### Conclusion

No claim is allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within

Application/Control Number: 09/686,964

Art Unit: 1648

Page 7

TWO MONTHS of the mailing date of this final action and the advisory action is not

mailed until after the end of the THREE-MONTH shortened statutory period, then the

shortened statutory period will expire on the date the advisory action is mailed, and any

extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

the advisory action. In no event, however, will the statutory period for reply expire later

than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Myron G. Hill whose telephone number is 571-272-

0901. The examiner can normally be reached on 9am-6pm Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, James Housel can be reached on 571-272-0902. The fax phone number for

the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have guestions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

Myroh G. Hill Patent Examiner September 7, 2004

SUPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1600